Equibles does not estimate personal net worth.
Get an email with a short summary when Supernus Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get SUPN alertsTim Dec is recorded as CFO at Supernus Pharmaceuticals, Inc. (SUPN). Tim Dec has spoken on 14 earnings calls across 1 company, most recently for Supernus Pharmaceuticals, Inc. on February 24, 2026. Supernus Pharmaceuticals, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Supernus Pharmaceuticals, Inc. includes Jack A. Khattar (CEO and Board Member), Jack Khattar (CEO and Board Member), Tony Kingsley (Chairman) and 7 others.
“As I review our first quarter 2025 results, please refer to today's press release and 10-Q that was filed earlier today. Total revenue for the first quarter of 2025 was $149.8 million compared to $143.6 million in the first quarter of 2024.”
“As I review our third quarter 2024 results, please refer to today's press release and 10-Q that were filed earlier today. Total revenue for the third quarter of 2024 was $175.7 million compared to $153.9 million in the same quarter last year.”
“As I review our second quarter 2024 results, please refer to today's press release and the 10-Q that were filed earlier today. Total revenue for the second quarter of 2024 was $168.3 million compared to $135.5 million in the same quarter last year.”
“As I review our fourth quarter and full year 2023 results, please refer to today's press release and 10-K that was filed earlier today. Total revenue for the fourth quarter of 2023 was $164.3 million, compared to $167.3 million in the prior year quarter.”
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
